BioCardia, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Collaboration agreement revenue | $0-100.0% | $58K-87.8% | $477K-64.7% | $1.4M+33.2% | $1.0M |
| Research and development | $5.0M+13.1% | $4.4M-43.2% | $7.7M-12.5% | $8.8M+3.2% | $8.6M |
| Selling, general and administrative | $3.3M-9.7% | $3.7M-16.5% | $4.4M-0.5% | $4.4M-13.1% | $5.1M |
| Total costs and expenses | $8.3M+2.7% | $8.1M-33.5% | $12.1M-8.5% | $13.3M-2.9% | $13.6M |
| Operating loss | -$8.3M-3.5% | -$8.0M+31.3% | -$11.6M+2.2% | -$11.9M+5.8% | -$12.6M |
| Total other income, net | $50K-9.1% | $55K-24.7% | $73K+1316.7% | -$6K-185.7% | $7K |
| Net loss | -$8.2M-3.5% | -$7.9M+31.3% | -$11.6M+2.8% | -$11.9M+5.7% | -$12.6M |
| Net loss per share, basic and diluted (in dollars per share) | -$1230.00+57.6% | -$2900.00+64.6% | -$8190.00-1122.4% | -$670.00+10.7% | -$750.00 |
| Weighted-average shares used in computing net loss per share, basic and diluted (in shares) | $6666943000.00+143.0% | $2743828000.00+94.3% | $1411998000.00-92.0% | $17720972000.00+4.7% | $16917664000.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-21 | Altman Peter | Director & President and CEO | Purchase | 1,500 | $0.92 | $1K | 293.3K | View | |
| 2026-05-19 | 2026-05-21 | Altman Peter | Director & President and CEO | Purchase | 200 | $0.95 | $190.00 | 291.8K | View | |
| 2026-05-18 | 2026-05-18 | Altman Peter | Director & President and CEO | Purchase | 5,700 | $0.92 | $5K | 291.6K | View | |
| 2026-05-15 | 2026-05-15 | Altman Peter | Director & President and CEO | Purchase | 5,100 | $1.02 | $5K | 285.9K | View | |
| 2026-04-29 | 2026-04-29 | Altman Peter | Director & President and CEO | Purchase | 5,000 | $1.11 | $6K | 280.8K | View |
Informational purposes only, not investment advice.